The FDA-approved data is for an analog, not native GLP-2
Teduglutide — an FDA-approved analog of GLP-2 (approved 2012 for adults, extended to pediatric patients in 2019), differing from native GLP-2 by one amino-acid substitution specifically to extend its half-life — is what the real human trial data covers, not native GLP-2 itself.
Benefits
GLP-2 promotes intestinal mucosal growth, improves gastric emptying/secretion, increases intestinal blood flow, barrier function, and absorption. Teduglutide Phase III trial, short bowel syndrome: more than 20% reduction in parenteral nutrition dependence was observed in treated patients. This is real, FDA-reviewed efficacy data — for the modified analog, not native GLP-2.
Isn't this the same as the GLP-1 weight-loss peptides?+
No, genuinely different jobs despite the similar name. GLP-1 manages blood sugar, appetite, and stomach emptying. GLP-2 is specifically about repairing and growing your intestinal lining, not weight or metabolism.
How does it actually repair the gut?+
It's considered the most potent known stimulator of intestinal lining growth — it expands the stem cell population in your gut and increases both the height and depth of the intestinal lining's structure, directly increasing how much surface area you have to absorb nutrients.
Looking for something specific, or placing a wholesale order? Send us a DM or email.